ArticleMolecular medicine (Cambridge, Mass.)2025
POC1A induces epithelial-mesenchymal transition to promote growth and metastasis through the STAT3 signaling pathway in triple-negative breast cancer.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- POC1A promotes the proliferation, metastasis and stemness of bladder cancer by stabilizing BMI1 via USP7.Oncogene · 2026Article
- The sialyltransferase ST3GAL1 mediates MUCL1 sialylation to exacerbate breast cancer progression.Human cell · 2026Article
- POC1A promotes malignant phenotypes in non-triple-negative breast cancer cell models with EMT- and Wnt/β-catenin-related alterations.Frontiers in oncology · 2026Article
- Correction: POC1A induces epithelial-mesenchymal transition to promote growth and metastasis through the STAT3 signaling pathway in triple-negative breast cancer.Molecular medicine (Cambridge, Mass.) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
objectivesTriple-negative breast cancer (TNBC) is known for its aggressiveness, which can be attributed to its heterogeneity, metastasis, and invasion capabilities. POC1 centriolar protein homolog A (POC1A), a centriolar protein involved in the formation of stable centrioles, has been associated with both cancer promotion and suppression in various malignant tumors. However, the underlying mechanisms that drive POC1A-induced metastases in TNBC remain to be elucidated.
methodsThe expression of POC1A changes and their clinical significance have been evaluated using TNBC tissues and a database. POC1A expression was examined in clinical samples and cells. The impacts of POC1A on the epithelial-mesenchymal transition's (EMT) relative factor expression was examined using immunofluorescence (IF), transcription-quantitative PCR (RT-qPCR), and Western blotting. We investigated the migration and invasion capabilities of TNBC cells and found that the patterns of tumor growth and metastasis varied correspondingly in different xenograft models. RNA sequencing (RNA-seq) was performed to explore the signaling pathways involved in POC1A, which was verified by several experiments.
resultsOur study identified an increase in the expression of POC1A in TNBC tissues, which was found to correlate with tumor size and lymph node metastasis. Meanwhile, POC1A plays a crucial role in the process of EMT, regulating the invasion and metastasis of TNBC in vitro and in vivo. Our RNA sequence results, followed by further investigation, revealed that POC1A promotes the metastasis of TNBC by inducing EMT through the STAT3 signaling pathway.
conclusionsIn short, for the first time, we have identified that POC1A plays a pivotal role in regulating the EMT of TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.